Castration-resistant prostate carcinoma

This study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers m…

This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lo…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

Researchers are testing whether giving radiation therapy before sipuleucel-T, a personalized immunotherapy vaccine, works better than the vaccine alone in men with hormone-resistant prostate cancer that has spread. The trial enrolls about 51 participants and randomly assigns them…

This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…

This trial asks men with advanced prostate cancer which of two oral medications they prefer: the experimental drug ODM-201 or the approved drug enzalutamide. Both work by blocking male hormones that fuel cancer growth. Participants will take each drug for a period and then answer…

This study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alo…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This clinical trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard hormone therapy enzalutamide (Xtandi) helps men with a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). The study includes men …

This study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, po…

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…

This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how …

This completed phase II trial tested whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. Nineteen men with metastatic castration-res…

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…

This phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study…

This study tested a combination of two targeted drugs (pertuzumab and trastuzumab) plus a chemotherapy drug (enzalutamide) in 7 men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to see if the combination could shrink or slow the gr…

This study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male horm…

This study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…

This study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumor…

This early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combinatio…

This Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safet…

This early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to se…

This early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other…

This early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the…

This early-phase trial tested an experimental cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest and most effective dose by measuring immune cell activity, PSA levels, and tumor changes. …

This study tested a combination of abiraterone acetate and prednisone in 131 men with advanced prostate cancer that had not yet spread on scans. The goal was to see if the drugs could lower PSA levels and delay cancer progression. Participants took daily pills alongside standard …

This study tested the immunotherapy drug nivolumab (Opdivo) combined with one of three other drugs (rucaparib, docetaxel, or enzalutamide) in 292 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to see if these combinations…

This study tested a drug called enzalutamide in 1401 men with a type of prostate cancer that has not spread to other parts of the body but is no longer controlled by standard hormone therapy. The goal was to see if enzalutamide could delay the cancer from spreading. Participants …

This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. …

This study tested whether adding focused radiation to standard hormone therapy or chemotherapy helps men with prostate cancer that has spread to a few spots (oligometastatic) and is no longer responding to hormone therapy alone. Fourteen participants received either standard trea…

This phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants…

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors or slow progression in men with metastatic castration-resistant prostate cancer. 351 participants received either the combination, ipilimumab alone, or the chemother…

This early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that t…

This study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair issues. The goal was to see if the drug could shrink tumors or slow the disease. Results may help identify which patients coul…

This early-phase trial tested a combination of three drugs—cabozantinib, abiraterone, and nivolumab—in 18 men with metastatic hormone-sensitive prostate cancer that had not yet been treated. The main goal was to find a safe dose and check for serious side effects. Researchers als…

This early-phase study tested a new treatment schedule for men with castration-resistant prostate cancer. The approach alternates between giving testosterone through the skin and the drug enzalutamide, aiming to control the disease. The main goals were to see if this schedule is …

This study tested an experimental drug called CPI-1205 combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and stopped responding to usual horm…

This phase 3 study tested the drug enzalutamide in 395 Asian men with metastatic prostate cancer that had stopped responding to standard hormone therapy. Participants had not yet received chemotherapy. The study compared enzalutamide to a placebo to see if it could delay rises in…

This phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resista…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This early-phase trial tested a combination of two drugs—docetaxel (a chemotherapy) and radium 223 (a radioactive drug)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goal was to find the safest dose and wa…

This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…

This phase 2 trial tested a combination of testosterone and olaparib in 36 men with castration-resistant prostate cancer. The idea is that testosterone can cause DNA damage in cancer cells that have adapted to low testosterone, while olaparib blocks the cells' ability to repair t…

This study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control t…

This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs …

This trial tested a steroid injection called triamcinolone in 55 men with castration resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to see if it could extend the time before chemotherapy is needed, since current steroid treatme…

This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is sa…

This pilot study tested whether a special PET scan (18F-fluciclovine) can better track how advanced prostate cancer responds to treatment compared to standard CT and bone scans. Nine men with metastatic castration-resistant prostate cancer received the scan before and 12 weeks af…

This study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choi…

This study looks at medical records from 584 men in Brazil with castration-resistant metastatic prostate cancer, a form of the disease that no longer responds to hormone therapy. Researchers aim to describe how long these patients survive and to identify their individual characte…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …

This study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is …

This study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…

This study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how th…

This study looked at medical records from over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer. The goal was to understand how the…

This study analyzed blood samples from 33 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers looked for tiny molecules called microRNAs that might predict whether a patient will resist chemotherapy or newer hormone drugs. The goal is to help…

This completed study looked at over 1,000 men with metastatic prostate cancer in the Pirkanmaa region of Finland. Researchers analyzed patient characteristics, treatments used, and outcomes to better understand the disease burden. The goal was to fill gaps in knowledge about how …

This study looked at whether a blood test could predict how prostate cancer responds to the drug abiraterone. Instead of taking a tissue sample (biopsy), researchers measured tumor cells circulating in the blood of 40 men with advanced prostate cancer. The goal was to see if chan…

This study followed over 1,400 men with metastatic castration-resistant prostate cancer who were already receiving Radium-223 as part of their routine care. Researchers tracked serious side effects and the development of new cancers over several years. The goal was to better unde…

This study looked at how the drug radium-223 spreads in the bones of men with prostate cancer that has spread to bones. Researchers gave the drug intravenously every 4 weeks for up to 6 doses and used imaging scans to measure its distribution in both tumor and healthy bone. The g…